Base de dados : MEDLINE
Pesquisa : D12.776.124.050.250 [Categoria DeCS]
Referências encontradas : 29107 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2911 ir para página                         

  1 / 29107 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329093
[Au] Autor:Pérez-Escalante E; González-Olivares LG; Cruz-Guerrero AE; Galán-Vidal CA; Páez-Hernández ME; Álvarez-Romero GA
[Ad] Endereço:Universidad Autónoma del Estado de Hidalgo, Área Académica de Química, Ciudad del Conocimiento, Carretera Pachuca-Tulancingo km 4.5, Colonia Carboneras, CP 42184 Mineral de la Reforma, Hidalgo, Mexico. Electronic address: emmanuel_perez@uaeh.edu.mx.
[Ti] Título:Size exclusion chromatography (SEC-HPLC) as an alternative to study thrombin inhibition.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1074-1075:34-38, 2018 Feb 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In vitro analysis of anticoagulant compounds with a potential use as antithrombotic drugs, has been traditionally performed using techniques like spectrophotometry, turbidimetry, as well as electrochemical and clinical assays. Although, these techniques have some disadvantages such as: the inability to measure the total biological activity of thrombin, interferences and, sometimes, the quantitative determination of the inhibition ratio is not accurate. In the present work, the conversion of fibrinogen to fibrin was monitored by molecular exclusion chromatography (SEC-HPLC) in three different reaction systems. An inhibition percentage of 43.19±2.02% was obtained using heparin as an anticoagulant, in addition to the determination of the percentage of heparin bonded to thrombin. This methodology has not been previously described and has high potential for the determination of anticoagulant capacity with higher precision, the determination of thrombin's total biological activity and the quantitative determination of the inhibition ratio.
[Mh] Termos MeSH primário: Cromatografia em Gel/métodos
Cromatografia Líquida de Alta Pressão/métodos
Fibrinogênio/metabolismo
Trombina/antagonistas & inibidores
[Mh] Termos MeSH secundário: Fibrina/análise
Fibrina/metabolismo
Fibrinogênio/análise
Heparina/farmacologia
Seres Humanos
Trombina/análise
Trombina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9001-31-4 (Fibrin); 9001-32-5 (Fibrinogen); 9005-49-6 (Heparin); EC 3.4.21.5 (Thrombin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE


  2 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254304
[Au] Autor:Li JK; Wang C; Gong HD; Li HZ
[Ad] Endereço:Department of Neurosurgery, Affiliated HongQi Hospital of Mu Dan Jiang Medical University, Mudanjiang City, China.
[Ti] Título:Coagulation in hindbrain membrane meningioma patients treated with different injections using acute hypervolemic hemodilution.
[So] Source:J Biol Regul Homeost Agents;31(4):991-996, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to analyze the changes in coagulation in meningioma patients treated with different injections using the method of acute hypervolemic hemodilution (AHH). One hundred fifty hindbrain membrane meningioma patients were randomly divided into 5 groups, 30 per group. The first group were injected 40ml/time with Danhong after anesthesia induction; the second group were injected with 40ml~60ml/time Kangai and combined with interventional chemotherapy and embolization procedure; the third group of AHH were injected with polygeline 15ml/kg; the fourth group were injected with hydroxyethyl starch (130/0.4) sodium chloride in doses of 15ml/kg; the control group underwent basic treatment for lowering blood pressure and lowering blood fat. The changes of coagulation index were recorded before and after surgery and before and after the injection of different medications. Compared to the control group, for the first group of AHH, after being treated for 10 days and 30 days, the concentrations of bone specific alkaline phosphatase (BALP), bone Gla protein (BGP) and pro-collagen carboxy-terminal propeptide (PICP) were higher than that of the control group, the levels of endotoxin (ET) and C-reactive protein (CRP) were decreased compared to the control group (p less than 0.05); for the second group of AHH, after being treated for 10 days, the index of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fg) were not significantly changed, but the related level of vascular endothelial growth factor (VEGF) significantly decreased (p less than 0.05). Comparing the coagulation function index after surgery in the third and fourth groups, there were no significant changes in mean arterial pressure (MAP) level, heart rate (HR) value presented a low decrease, central venous pressure (CVP) level increased and the level of interleukin IL-6 showed a steady state after increasing. Analyzing the levels of interleukin IL-8 and tumor necrosis factor-α (TNF-α) after surgery, it was seen that in the third group they increased and in the fourth group they decreased (p less than 0.05). Danhong injection improved the coagulation function and microcirculation of patients, Kangai injection and interventional chemotherapy and embolization restrained the appearance of tumor angiogenesis, AHH operation with polygeline injection and hydroxyethyl starch (130/0.4) sodium chloride kept blood flow in normal parameters.
[Mh] Termos MeSH primário: Coagulação Sanguínea/efeitos dos fármacos
Cardiotônicos/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Hemodiluição/métodos
Neoplasias Meníngeas/tratamento farmacológico
Meningioma/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Fosfatase Alcalina/genética
Fosfatase Alcalina/metabolismo
Pressão Arterial/efeitos dos fármacos
Pressão Arterial/fisiologia
Biomarcadores/metabolismo
Viscosidade Sanguínea/efeitos dos fármacos
Proteína C-Reativa/genética
Proteína C-Reativa/metabolismo
Embolização Terapêutica/métodos
Endotoxinas/metabolismo
Feminino
Fibrinogênio/genética
Fibrinogênio/metabolismo
Expressão Gênica
Frequência Cardíaca/efeitos dos fármacos
Frequência Cardíaca/fisiologia
Seres Humanos
Derivados de Hidroxietil Amido/administração & dosagem
Masculino
Neoplasias Meníngeas/sangue
Neoplasias Meníngeas/patologia
Neoplasias Meníngeas/cirurgia
Meningioma/sangue
Meningioma/patologia
Meningioma/cirurgia
Meia-Idade
Osteocalcina/genética
Osteocalcina/metabolismo
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/metabolismo
Substitutos do Plasma/administração & dosagem
Poligelina/administração & dosagem
Pró-Colágeno/genética
Pró-Colágeno/metabolismo
Rombencéfalo/efeitos dos fármacos
Rombencéfalo/metabolismo
Rombencéfalo/patologia
Rombencéfalo/cirurgia
Fator A de Crescimento do Endotélio Vascular/genética
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cardiotonic Agents); 0 (Drugs, Chinese Herbal); 0 (Endotoxins); 0 (Hydroxyethyl Starch Derivatives); 0 (Peptide Fragments); 0 (Plasma Substitutes); 0 (Procollagen); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); 0 (danhong); 0 (procollagen type I carboxy terminal peptide); 104982-03-8 (Osteocalcin); 9001-32-5 (Fibrinogen); 9007-41-4 (C-Reactive Protein); 9015-56-9 (Polygeline); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  3 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774807
[Au] Autor:Stepanikova I; Oates GR; Bateman LB
[Ad] Endereço:a Department of Sociology , University of Alabama at Birmingham , Birmingham , AL , USA.
[Ti] Título:Does one size fit all? The role of body mass index and waist circumference in systemic inflammation in midlife by race and gender.
[So] Source:Ethn Health;22(2):169-183, 2017 04.
[Is] ISSN:1465-3419
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: This study investigates the associations of body mass index (BMI) and waist circumference (WC) with markers of systemic inflammation in midlife by race and gender. DESIGN: Data were obtained from the Survey of Midlife in the United States, a cross-sectional, observational study of Americans 35 years old or older (White men: N = 410; White women: N = 490; Black men: N = 58; Black women: N = 117). Inflammation was measured by concentrations of fibrinogen and C-reactive protein (CRP) in fasting plasma and concentrations of E-selectin and interleukin-6 (IL-6) in fasting serum. Anthropometric data were used to obtain BMI and WC. Socio-demographic and health-related factors were assessed with a survey. Multivariate models by race and gender were estimated to test the roles of BMI and WC for each inflammation marker. RESULTS: Compared to White men, Black women have higher BMI and higher levels of all four inflammation markers; White women have lower BMI, lower WC, and lower E-selectin and fibrinogen but higher CRP; and Black men have higher fibrinogen. After adjusting for socio-demographic and health-related covariates as well as perceived discrimination, WC is associated with all four markers of inflammation among White men and women; with three markers (fibrinogen, CRP, and IL-6) of inflammation among Black women; and with CRP (and marginally with fibrinogen and E-selectin) among Black men. BMI is associated with higher CRP and fibrinogen among Black men (marginally so for White men) but not for women of either race. CONCLUSIONS: WC shows more consistent associations with inflammation markers than BMI, although the relationships vary by inflammation marker and population group. Our findings suggest that WC is a risk factor for systemic inflammation among White and Black men and women, and BMI is an additional risk factor for Black men.
[Mh] Termos MeSH primário: Afroamericanos/estatística & dados numéricos
Índice de Massa Corporal
Grupo com Ancestrais do Continente Europeu/estatística & dados numéricos
Inflamação/etnologia
Circunferência da Cintura
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores
Pesos e Medidas Corporais
Proteína C-Reativa/biossíntese
Estudos Transversais
Selectina E/biossíntese
Feminino
Fibrinogênio/biossíntese
Seres Humanos
Inflamação/fisiopatologia
Mediadores da Inflamação
Interleucina-6/biossíntese
Masculino
Meia-Idade
Fatores de Risco
Fatores Sexuais
Fatores Socioeconômicos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (E-Selectin); 0 (Inflammation Mediators); 0 (Interleukin-6); 9001-32-5 (Fibrinogen); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1080/13557858.2016.1235681


  4 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365372
[Au] Autor:Fang X; Yu LS; Ma X; Xia RM; Jiang YH; Liu HX; Jing YY
[Ad] Endereço:Department of Otorhinolaryngology, People's Hospital of Peking University, Beijing 100044, China (now working at Human Anatomy Teaching and Research Department of Health Science Center of Peking University).
[Ti] Título:[Correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):3-8, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To analyze the correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness, and to explore the individualized treatment strategy for the use of Batroxobin. Patients with all-frequency sudden deafness who were admitted to Department of Otorhinolaryngology, People's Hospital of Peking University, from January 2010 to September 2016 were selected. All patients were given standard treatment and regular use of Batroxobin. Value of fibrinogen on D1 (before treatment) / D3 / D7 (±1) and D14 (±2) were recorded, at the same time, the correlation between the changes of fibrinogen and prognosis of all-frequency sudden deafness by the audiograms of onset and after-treatment of all patients were analyzed. Independent -test was used to analyze normal distributed measurement data and chi square linear trend test was used to analyze the curative effect of different fibrinogen groups. A total of 148 patients were included, the outcomes were worst when the patient's fibrinogen was below 2 g/L or above 4 g/L before treatment, ineffective rate were both 50%. The fibrinogen was lowest when the treatment came to the third day. Normally, the patient's prognosis was best when this value waved between 0.7 and 0.9 g/L, with a total effective rate between 73.9% and 83.3%. The fibrinogen value of the 7th day was a good indicator of the outcome, and Fib7 value was significant lower in patients of effective group than ineffective ones ((1.25±0.37)g/L (1.38±0.35) g/L, =-0.27, =0.04). Patients found a best recovery when Fib7 was below 1 g/L, and the higher the Fib7 value, the higher the inefficiency (χ(2)=7.55, =0.01). Batroxobin showed safety during the treatment and found no complications. The change of fibrinogen in the process of all-frequency sudden deafness is closely related to the curative effect.
[Mh] Termos MeSH primário: Batroxobina/farmacologia
Fibrinogênio/efeitos dos fármacos
Fibrinolíticos/farmacologia
Perda Auditiva Súbita/sangue
Perda Auditiva Súbita/tratamento farmacológico
[Mh] Termos MeSH secundário: Distribuição de Qui-Quadrado
Fibrinogênio/análise
Testes Auditivos
Seres Humanos
Prognóstico
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 9001-32-5 (Fibrinogen); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.002


  5 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320623
[Au] Autor:Kulic A; Cvetkovic Z; Libek V
[Ti] Título:Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report.
[So] Source:Vojnosanit Pregl;73(9):877-80, 2016 Sep.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: A bleeding syndrome in the setting of primary hyperfibrinolysis in a prostate cancer patient is only 0.40­ 1.65% of cases. The laboratory diagnosis of primary hyperfibrinolysis is based on the increase of biomarkers like D-dimer, fibrinogen split products, plasminogen, and euglobulin lysis test. These tests are not specific for primary hyperfibrinolysis. We reported a rare case of hemorrhagic syndrome caused by primary hyperfibrinolysis as the first clinical symptom of metastatic prostate cancer. Case report: A 64-year-old male was admitted to our hospital with large hematomas in the right pectoral and axillary areas (20 x 7 cm), right hemiabdomen (30 x 30 cm) and the left lumbal area, (25 x 5 cm). The patient had no subjective symptoms nor used any medication. Initial coagulation testing, prothrombin time (PT), and activated partial thromboplastin time (APTT) were within the normal range, while fibrinogen level was extremely low (1.068 g/L) (normal range 2.0­5.0) and the D-dimer assay result was high 1.122 mg/L (normal range < 0.23). The results obtained by rotation thrombelastometry pointed to primary fibrinolysis. Further clinical and laboratory examination indicated progressive malignant prostate disease. First line treatment for the patient was a combined administration of tranexamic acid (3 x 500 mg iv) and transfusion of ten units of cryoprecipitate (400 mL). Next day, fibrinolytic function measurements by rotation thrombelastometry were within the normal ranges. Fibrinogen level was normalized within two days (2.4 g/L). There were no newly developed hematomas. Conclusion: This case report shows primary hyperfibrinolysis with bleeding symptoms, which is an uncommon paraneoplastic phenomenon within expanded prostate malignancy. Rotation thrombelastometry in this severe complication helped to achieve the prompt and proper diagnosis and treatment.
[Mh] Termos MeSH primário: Adenocarcinoma/complicações
Transtornos da Coagulação Sanguínea/etiologia
Fibrinólise
Síndromes Paraneoplásicas/etiologia
Neoplasias da Próstata/complicações
[Mh] Termos MeSH secundário: Adenocarcinoma/sangue
Adenocarcinoma/secundário
Adenocarcinoma/terapia
Antifibrinolíticos/uso terapêutico
Biomarcadores/sangue
Transtornos da Coagulação Sanguínea/sangue
Transtornos da Coagulação Sanguínea/diagnóstico
Transtornos da Coagulação Sanguínea/tratamento farmacológico
Testes de Coagulação Sanguínea
Neoplasias Ósseas/secundário
Fator VIII/uso terapêutico
Fibrinogênio/uso terapêutico
Fibrinólise/efeitos dos fármacos
Hematoma/etiologia
Hemorragia/etiologia
Seres Humanos
Masculino
Meia-Idade
Síndromes Paraneoplásicas/sangue
Síndromes Paraneoplásicas/diagnóstico
Síndromes Paraneoplásicas/tratamento farmacológico
Neoplasias da Próstata/sangue
Neoplasias da Próstata/patologia
Neoplasias da Próstata/terapia
Ácido Tranexâmico/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifibrinolytic Agents); 0 (Biomarkers); 0 (cryoprecipitate coagulum); 6T84R30KC1 (Tranexamic Acid); 9001-27-8 (Factor VIII); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150525076K


  6 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454486
[Au] Autor:Eichinger CD; Hlady V
[Ad] Endereço:Department of Bioengineering, University of Utah, 20 S. 2030 E., Rm. 108A, Salt Lake City, Utah 84112.
[Ti] Título:Binary agonist surface patterns prime platelets for downstream adhesion in flowing whole blood.
[So] Source:Biointerphases;12(2):02C406, 2017 04 28.
[Is] ISSN:1559-4106
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:As platelets encounter damaged vessels or biomaterials, they interact with a complex milieu of surface-bound agonists, from exposed subendothelium to adsorbed plasma proteins. It has been shown that an upstream, surface-immobilized agonist is capable of priming platelets for enhanced adhesion downstream. In this study, binary agonists were integrated into the upstream position of flow cells and the platelet priming response was measured by downstream adhesion in flowing whole blood. A nonadditive response was observed in which platelets transiently exposed to two agonists exhibited greater activation and downstream adhesion than that from the sum of either agonist alone. Antibody blocking of one of the two upstream agonists eliminated nonadditive activation and downstream adhesion. Crosstalk between platelet activation pathways likely led to a synergistic effect which created an enhanced activation response in the platelet population. The existence of synergy between platelet priming pathways is a concept that has broad implications for the field of biomaterials hemocompatibility and platelet activity testing.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Plaquetas/metabolismo
[Mh] Termos MeSH secundário: Anticorpos/imunologia
Materiais Biocompatíveis/farmacologia
Plaquetas/citologia
Adesão Celular/efeitos dos fármacos
Colágeno Tipo I/química
Colágeno Tipo I/imunologia
Fibrinogênio/química
Fibrinogênio/imunologia
Citometria de Fluxo/instrumentação
Citometria de Fluxo/métodos
Seres Humanos
Propriedades de Superfície
Fator de von Willebrand/química
Fator de von Willebrand/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antibodies); 0 (Biocompatible Materials); 0 (Collagen Type I); 0 (von Willebrand Factor); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.1116/1.4982596


  7 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778058
[Au] Autor:Michalski CW; Tramelli P; Büchler MW; Hackert T
[Ad] Endereço:Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
[Ti] Título:[Closure of pancreas stump after distal and segmental resection : Suture, stapler, coverage or anastomosis?]
[Ti] Título:Verschluss des Pankreasstumpfes bei Links- und Segmentresektion : Naht, Stapler, Deckung oder Anastomose?.
[So] Source:Chirurg;88(1):25-29, 2017 Jan.
[Is] ISSN:1433-0385
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Postoperative pancreatic fistulas represent the most frequent complication after distal and segmental pancreatectomy and occur with a frequency of up to 50 %. There are many technical variations of pancreatic stump treatment for reduction of fistula rates after distal resection. Most of these techniques have only been analyzed in retrospective studies and the evidence for or against a specific technique is low. Several retrospective trials have been conducted with good results to compare suturing with stapled closure of the remnant and to assess the effect of a vascularized falciform ligament patch in reducing postoperative pancreatic fistula; however, in a recently published randomized trial, which analyzed closure of the remnant with a pancreaticojejunostomy compared to standard closure, these results could not be confirmed. Because stapler resection and closure is the most commonly used technique in laparoscopic distal pancreatectomy, there are a large number of studies which assessed various novel methods of improving stapling. Extended stapler compression time and mesh augmentation of the stapler line can be valid methods to reduce fistula rates. Central pancreatectomy is a relatively rarely used procedure where the right-sided pancreatic remnant is closed in the same fashion as during distal pancreatectomy and the left-sided remnant is connected to the intestines with a pancreaticojejunostomy or pancreaticogastrostomy. In conclusion, postoperative pancreatic fistula rates are still a relevant clinical problem after distal pancreatectomy and further studies on potentially improved novel techniques are required.
[Mh] Termos MeSH primário: Anastomose Cirúrgica/métodos
Pancreatectomia/métodos
Fístula Pancreática/prevenção & controle
Complicações Pós-Operatórias/prevenção & controle
Grampeamento Cirúrgico/métodos
Técnicas de Sutura
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Adesivo Tecidual de Fibrina/administração & dosagem
Fibrinogênio/administração & dosagem
Seres Humanos
Pancreaticojejunostomia/métodos
Fatores de Risco
Ligamento Redondo do Fígado/cirurgia
Telas Cirúrgicas
Trombina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Fibrin Tissue Adhesive); 0 (TachoSil); 9001-32-5 (Fibrinogen); EC 3.4.21.5 (Thrombin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s00104-016-0301-3


  8 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381980
[Au] Autor:Zhang B; Liu G; Liu X; Zheng S; Dong K; Dong R
[Ad] Endereço:Children's Hospital of Fudan University.
[Ti] Título:Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients.
[So] Source:Medicine (Baltimore);96(47):e8798, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Hepatoblastoma (HB) is the most common pediatric liver malignancy, typically affecting children within the first 4 years of life. However, only a few validated blood biomarkers are used in clinical evaluation. The current study explored the clinical application and significance of D-dimer levels in patients with HB. METHOD: Forty-four patients with HB were included in this retrospective study. D-dimer and plasma fibrinogen levels were examined, and their correlation with other clinical features was analyzed. D-dimer and plasma fibrinogen levels were examined between HB and other benign hepatic tumors. RESULTS: D-dimer levels were significantly associated with high-risk HB features, such as advanced stage and high α-fetoprotein (AFP) levels. Higher D-dimer levels were observed in stage 4 patients compared with stage 1/2/3 patients (P = .028). Higher D-dimer levels were also observed in patients with higher AFP levels before chemotherapy compared with patients with lower AFP levels after chemotherapy (P< 0.001). In addition, higher D-dimer levels were observed in HB compared with other benign hepatic tumors such as hepatic hemangioma and hepatocellular adenoma (P = .012). No significant difference in D-dimer levels was found between sex (P = .503) and age (≥12 vs <12 months, P = .424). There was no significant difference in plasma fibrinogen levels between sex or age and high-risk HB features, such as advanced stage and high AFP levels. CONCLUSIONS: Elevated D-dimer levels could be a useful determinant biomarker for high-risk features in patients with HB. This finding also supports the clinical application of D-dimer in HB.
[Mh] Termos MeSH primário: Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Hepatoblastoma/sangue
Neoplasias Hepáticas/sangue
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/sangue
Criança
Pré-Escolar
Feminino
Fibrinogênio/análise
Seres Humanos
Lactente
Recém-Nascido
Masculino
Estudos Retrospectivos
alfa-Fetoproteínas/análise
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Fibrin Fibrinogen Degradation Products); 0 (alpha-Fetoproteins); 0 (fibrin fragment D); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008798


  9 / 29107 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374746
[Au] Autor:Palaj J; Keckés S; Marek V; Dyttert D; Waczulíková I; Durdík S
[Ad] Endereço:Department of Oncological Surgery, St. Elizabeth Cancer Institute, Slovak Republic and Faculty of Medicine in Bratislava of the Comenius University, Bratislava, Slovak Republic julius.palaj@ousa.sk.
[Ti] Título:Fibrinogen Levels Are Associated with Lymph Node Involvement and Overall Survival in Gastric Cancer Patients.
[So] Source:Anticancer Res;38(2):1097-1104, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Combination of perioperative chemotherapy with gastrectomy with D2 lymphadenectomy improves long-term survival in patients with gastric cancer. The aim of this study was to investigate the predictive value of preoperative levels of CRP, albumin, fibrinogen, neutrophil-to-lymphocyte ratio and routinely used tumor markers (CEA, CA 19-9, CA 72-4) for lymph node involvement. MATERIALS AND METHODS: This retrospective study was conducted in 136 patients who underwent surgery between 2007 and 2015. Bivariable and multivariable analyses were performed in order to identify important characteristics associated with the risk of lymph node involvement. Kaplan-Meier survival curves and log-rank tests were used to compare overall survival. RESULTS: Lymph node involvement was significantly affected by preoperative fibrinogen (p=0.008) and albumin (p=0.023). Poor clinical condition, T and N staging and fibrinogen level above 3.5 g/l were significantly associated with worse overall survival. CONCLUSION: Preoperative fibrinogen and albumin levels are significantly associated with lymphoid metastases in patients with gastric cancer.
[Mh] Termos MeSH primário: Fibrinogênio/metabolismo
Gastrectomia/mortalidade
Excisão de Linfonodo/mortalidade
Linfonodos/patologia
Neoplasias Gástricas/mortalidade
[Mh] Termos MeSH secundário: Idoso
Biomarcadores Tumorais/metabolismo
Feminino
Seguimentos
Seres Humanos
Linfonodos/cirurgia
Metástase Linfática
Masculino
Meia-Idade
Prognóstico
Estudos Retrospectivos
Neoplasias Gástricas/cirurgia
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  10 / 29107 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29227068
[Au] Autor:Ohe M; Mutsuki T; Goya T; Yamashita S; Satoh T; Kohjima M; Kato M
[Ti] Título:Portal Vein Thrombosis Repeatedly Observed in a Cirrhotic Patient with Antiphospholipid Antibody Syndrome.
[So] Source:Fukuoka Igaku Zasshi;107(10):185-90, 2016 Oct.
[Is] ISSN:0016-254X
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Background: Although portal vein thrombosis in cirrhotic patients is frequently observed, the detailed process remains to be clarified, and the role of anticardiolipin antibody in the development of portal vein thrombosis has been controversial. Case Report: A 52-year-old man, who had been diagnosed with alcoholic cirrhosis of the liver, was admitted to our hospital suffering from dyspnea and ascites. Just after being diagnosed as having antiphospholipid antibody syndrome with lung thrombosis and delivering a positive result for the ß 2-glycoprotein I-dependent anticardiolipin antibody, he sustained rupture of the esophageal varices with rapid development of portal vein thrombosis, which resolved under anticoagulant therapy. Two years later, he was admitted again on suspicion of thrombosis because of an elevation in the serum D-dimer level, and computed tomography showed portal and upper mesenteric vein thrombosis. Although immediate anticoagulant therapy resulted in complete recanalization, he suffered the same episode 2 months later, which occurred with re-elevation of the serum D-dimer level. Conclusion: A positive finding of an anticardiolipin antibody in cirrhotic patients has been considered to be nonspecific and not related to the development of thrombus in the portal vein. This case, however, seems to indicate that cirrhotic patients with the ß2-glycoprotein I-dependent anticardiolipin antibody should be regarded as being at high risk for portal vein thrombosis. Monitoring with the serum D-dimer was useful in detecting portal vein thrombosis in its early stage.
[Mh] Termos MeSH primário: Síndrome Antifosfolipídica/diagnóstico por imagem
Cirrose Hepática/diagnóstico por imagem
Veia Porta/diagnóstico por imagem
Trombose Venosa/diagnóstico por imagem
Trombose Venosa/etiologia
[Mh] Termos MeSH secundário: Síndrome Antifosfolipídica/complicações
Fibrina/metabolismo
Fibrinogênio/metabolismo
Seres Humanos
Cirrose Hepática/complicações
Masculino
Meia-Idade
Tomografia Computadorizada por Raios X
Trombose Venosa/metabolismo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9001-31-4 (Fibrin); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE



página 1 de 2911 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde